全球鹦鹉热治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计鹦鹉热治疗市场将从 2025 年的 2.3169 亿美元成长到 2034 年的 3.9914 亿美元，2026 年至 2034 年的复合年增长率为 6.23%。

随着人们对禽类传染给人类的通用感染疾病的认识不断提高，全球鹦鹉热治疗市场正在稳步增长。鹦鹉热是由披衣菌感染衣原体引起，需要及时使用抗生素治疗以预防严重呼吸系统的併发症。宠物饲养量的增加和家禽养殖业的扩张导致感染风险上升，从而推动了对有效治疗方案的需求。医疗保健机构正着重强调早期诊断和适当的抗菌治疗。

成长要素包括诊断能力的提升和感染疾病监测系统的加强。政府为控制通用感染疾病爆发所做的努力正在加强医疗卫生体系。频谱抗生素的广泛应用和诊断技术的进步正在改善治疗效果。此外，公共卫生教育宣传活动的增加正在促进早期医疗干预，并减少因延迟诊断而导致的併发症。

展望未来，抗生素抗药性和标靶治疗研究的进展预计将推动市场发展。兽医学与人类医疗保健领域合作的加强有望改善疾病管理策略。新兴经济体对感染疾病控制项目的投资正在创造新的成长机会。随着全球卫生监测体系的不断完善，鹦鹉热治疗市场预计将稳定扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球鹦鹉热治疗市场：按类型划分

• 市场分析、洞察与预测
• 鹦鹉热披衣菌感染
• 鸡
• 火鸡
• 鸽子
• 虎皮鹦鹉

第五章：全球鹦鹉热治疗市场：依抗生素类型划分

• 市场分析、洞察与预测
• 四环霉素
• 兰姆酒
• 多西环素

第六章：全球鹦鹉热治疗市场：依治疗类型划分

• 市场分析、洞察与预测
• 药物
• 抗生素治疗
• 支持性护理

第七章：全球鹦鹉热治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外
• 静脉注射

第八章：全球鹦鹉热治疗市场：以购买方式划分

• 市场分析、洞察与预测
• 处方笺
• 非处方药

第九章：全球鹦鹉热治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房
• 其他的

第十章 全球鹦鹉热治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲

第十一章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十二章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Sanofi
  • Abbott
  • Walter Bushnell
  • ARISTO Pharmaceuticals Private Limited
  • Pfizer Inc
  • Jagsonpal
  • Dr. Reddy'S Laboratories Ltd
  • USV Private Limited
  • Bristol-Myers Squibb Company
  • GSK Plc
  • F. Hoffmann-La Roche Ltd
  • BioCryst Pharmaceuticals Inc

The Psittacosis Treatment Market size is expected to reach USD 399.14 Million in 2034 from USD 231.69 Million (2025) growing at a CAGR of 6.23% during 2026-2034.

The Global Psittacosis Treatment Market is growing steadily due to increasing awareness of zoonotic infections transmitted from birds to humans. Psittacosis, caused by Chlamydia psittaci bacteria, requires timely antibiotic treatment to prevent severe respiratory complications. Rising pet ownership and poultry farming activities have increased the risk of transmission, thereby supporting demand for effective treatment solutions. Healthcare providers are emphasizing early diagnosis and appropriate antimicrobial therapy.

Key growth drivers include improved diagnostic capabilities and greater surveillance of infectious diseases. Government initiatives aimed at controlling zoonotic outbreaks are strengthening healthcare preparedness. The growing availability of broad-spectrum antibiotics and advancements in laboratory testing are enhancing treatment outcomes. Additionally, rising public health education campaigns are promoting early medical intervention, reducing complications associated with delayed diagnosis.

In the future, increased research into antimicrobial resistance and targeted therapies is expected to shape market development. Enhanced collaboration between veterinary and human healthcare sectors will improve disease management strategies. Emerging economies are investing in infectious disease control programs, creating new growth avenues. As global health monitoring systems strengthen, the psittacosis treatment market is anticipated to expand steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Chlamydia Psittaci
• Chickens
• Turkeys
• Pigeons
• Parakeets

By Antibiotic Type

• Tetracycline
• Chloramphenicol
• Doxycycline

By Treatment Type

• Medication
• Antibiotic Therapy
• Supportive Care

By Route of Administration

• Oral
• Parenteral
• Intravenous

By Mode of Purchase

• Prescription
• Over the Counter

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• Sanofi, Abbott, Walter Bushnell, ARISTO Pharmaceuticals Private Limited, Pfizer Inc, Jagsonpal, Dr Reddys Laboratories Ltd, USV Private Limited, BristolMyers Squibb Company, GSK plc, F HoffmannLa Roche Ltd, BioCryst Pharmaceuticals Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PSITTACOSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Chlamydia Psittaci Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chickens Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Turkeys Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Pigeons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Parakeets Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PSITTACOSIS TREATMENT MARKET: BY ANTIBIOTIC TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Antibiotic Type
• 5.2. Tetracycline Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chloramphenicol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Doxycycline Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PSITTACOSIS TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Treatment Type
• 6.2. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Antibiotic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PSITTACOSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PSITTACOSIS TREATMENT MARKET: BY MODE OF PURCHASE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Mode Of Purchase
• 8.2. Prescription Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Over the Counter Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PSITTACOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Distribution Channel
• 9.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL PSITTACOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Type
  • 10.2.2 By Antibiotic Type
  • 10.2.3 By Treatment Type
  • 10.2.4 By Route Of Administration
  • 10.2.5 By Mode Of Purchase
  • 10.2.6 By Distribution Channel
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Type
  • 10.3.2 By Antibiotic Type
  • 10.3.3 By Treatment Type
  • 10.3.4 By Route Of Administration
  • 10.3.5 By Mode Of Purchase
  • 10.3.6 By Distribution Channel
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Russia
  • 10.3.12 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Type
  • 10.4.2 By Antibiotic Type
  • 10.4.3 By Treatment Type
  • 10.4.4 By Route Of Administration
  • 10.4.5 By Mode Of Purchase
  • 10.4.6 By Distribution Channel
  • 10.4.7 India
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 Australia
  • 10.4.11 South East Asia
  • 10.4.12 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Type
  • 10.5.2 By Antibiotic Type
  • 10.5.3 By Treatment Type
  • 10.5.4 By Route Of Administration
  • 10.5.5 By Mode Of Purchase
  • 10.5.6 By Distribution Channel
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 South East Asia
  • 10.5.12 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Type
  • 10.6.2 By Antibiotic Type
  • 10.6.3 By Treatment Type
  • 10.6.4 By Route Of Administration
  • 10.6.5 By Mode Of Purchase
  • 10.6.6 By Distribution Channel
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL PSITTACOSIS TREATMENT INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 Sanofi
  • 12.2.2 Abbott
  • 12.2.3 Walter Bushnell
  • 12.2.4 ARISTO Pharmaceuticals Private Limited
  • 12.2.5 Pfizer Inc
  • 12.2.6 Jagsonpal
  • 12.2.7 Dr. Reddy'S Laboratories Ltd
  • 12.2.8 USV Private Limited
  • 12.2.9 Bristol-Myers Squibb Company
  • 12.2.10 GSK Plc
  • 12.2.11 F. Hoffmann-La Roche Ltd
  • 12.2.12 BioCryst Pharmaceuticals Inc